IL267086A - Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors - Google Patents
Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptorsInfo
- Publication number
- IL267086A IL267086A IL267086A IL26708619A IL267086A IL 267086 A IL267086 A IL 267086A IL 267086 A IL267086 A IL 267086A IL 26708619 A IL26708619 A IL 26708619A IL 267086 A IL267086 A IL 267086A
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- modulators
- tyrosine kinases
- neurotrophin
- triazinetrione
- Prior art date
Links
- FKBYRZCVXYSLEL-UHFFFAOYSA-N 1h-triazine-4,5,6-trione Chemical class O=C1NN=NC(=O)C1=O FKBYRZCVXYSLEL-UHFFFAOYSA-N 0.000 title 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 title 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 title 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651706 | 2016-12-21 | ||
| PCT/GB2017/053868 WO2018115891A1 (en) | 2016-12-21 | 2017-12-21 | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL267086A true IL267086A (en) | 2019-08-29 |
Family
ID=60923799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267086A IL267086A (en) | 2016-12-21 | 2019-06-04 | Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113910A1 (https=) |
| EP (1) | EP3558320A1 (https=) |
| JP (1) | JP2020502225A (https=) |
| KR (1) | KR20190098982A (https=) |
| CN (1) | CN110167558A (https=) |
| AU (1) | AU2017380583A1 (https=) |
| BR (1) | BR112019012709A2 (https=) |
| CA (1) | CA3046289A1 (https=) |
| IL (1) | IL267086A (https=) |
| MX (1) | MX2019007606A (https=) |
| RU (1) | RU2019120431A (https=) |
| WO (1) | WO2018115891A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008816A (es) | 2018-02-26 | 2020-09-28 | AlzeCure Pharma AB | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113893334A (zh) * | 2021-10-19 | 2022-01-07 | 内蒙古医科大学第二附属医院 | 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| JP5785940B2 (ja) * | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス， エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
| US8901129B2 (en) * | 2009-12-11 | 2014-12-02 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
-
2017
- 2017-12-21 JP JP2019534090A patent/JP2020502225A/ja active Pending
- 2017-12-21 RU RU2019120431A patent/RU2019120431A/ru not_active Application Discontinuation
- 2017-12-21 EP EP17825283.9A patent/EP3558320A1/en not_active Withdrawn
- 2017-12-21 CA CA3046289A patent/CA3046289A1/en not_active Abandoned
- 2017-12-21 BR BR112019012709A patent/BR112019012709A2/pt not_active Application Discontinuation
- 2017-12-21 US US16/471,923 patent/US20200113910A1/en not_active Abandoned
- 2017-12-21 CN CN201780078675.XA patent/CN110167558A/zh active Pending
- 2017-12-21 AU AU2017380583A patent/AU2017380583A1/en not_active Abandoned
- 2017-12-21 WO PCT/GB2017/053868 patent/WO2018115891A1/en not_active Ceased
- 2017-12-21 KR KR1020197018642A patent/KR20190098982A/ko not_active Ceased
- 2017-12-21 MX MX2019007606A patent/MX2019007606A/es unknown
-
2019
- 2019-06-04 IL IL267086A patent/IL267086A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019012709A2 (pt) | 2019-11-26 |
| CA3046289A1 (en) | 2018-06-28 |
| AU2017380583A1 (en) | 2019-06-27 |
| RU2019120431A3 (https=) | 2021-03-09 |
| RU2019120431A (ru) | 2021-01-22 |
| JP2020502225A (ja) | 2020-01-23 |
| EP3558320A1 (en) | 2019-10-30 |
| CN110167558A (zh) | 2019-08-23 |
| US20200113910A1 (en) | 2020-04-16 |
| MX2019007606A (es) | 2020-07-29 |
| WO2018115891A1 (en) | 2018-06-28 |
| KR20190098982A (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267086A (en) | Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors | |
| IL274568A (en) | COT modulators and methods of using them | |
| IL275936A (en) | Variants of type IIB activin receptor and methods of using them | |
| ZA201708065B (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| IL265215B (en) | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy | |
| SG11201600055PA (en) | Protein tyrosine kinase modulators and methods of use | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| PL3600282T3 (pl) | Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy | |
| GB201721028D0 (en) | Authentication and authorisation | |
| ZA201800122B (en) | Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo | |
| IL280213A (en) | Altered quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | |
| IL266840A (en) | History of tyrosine and preparations containing them | |
| EP3448375C0 (en) | BENZOYLGLYCINE DERIVATIVES AND METHODS OF PRODUCING AND USING SUCH DERIVATIVES | |
| EP3171941A4 (en) | N-methyl-d-aspartate receptor modulators and methods of making and using same | |
| HK40015937A (en) | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases | |
| SG11201707739RA (en) | Celestial compass and methods of use and calibration | |
| IL237964A0 (en) | Leveling deviation meter and methods of use and calibration | |
| ZA202000399B (en) | Heterocyclylmethylidene derivatives and their use as modulators of mglur5 receptors | |
| HK40014733A (en) | Activin receptor type iia variants and methods of use thereof | |
| HK40014732A (en) | Activin receptor type iia variants and methods of use thereof | |
| ZA201600856B (en) | Protein tyrosine kinase modulators and methods of use | |
| ZA201704416B (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| HK40019799A (en) | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors | |
| GB201514761D0 (en) | Preparation and uses of pyrimidinone derivatives |